期刊
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
卷 29, 期 3, 页码 452-456出版社
WILEY
DOI: 10.1111/jdv.12576
关键词
-
类别
资金
- Swedish Board of Health and Welfare
- Swedish Association of Local Authorities and Regions
- Vasterbotten County Council
- Industrial Doctoral School, Umea University
BackgroundFollowing the establishment of the National Quality Registry for systemic psoriasis treatment (PsoReg), the two psoriasis outcome measurements, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), are now integrated in clinical practice in Sweden. According to current guidelines, the initiation of a biological treatment should depend on a combination of the physician's (PASI) and the patients' assessment of the disease impact on a health-related quality of life measure (DLQI). ObjectiveTo evaluate if either of the two measures, PASI or DLQI, is more strongly associated with initiation of biological therapy. MethodsThe study is based on 2216 patients suffering from moderate to severe psoriasis who were biological naive at enrolment to PsoReg. The relationship between the two measures PASI and DLQI and initiation of biological treatment (as outcome) were estimated by a logistic regression and a Cox proportional hazard's model with combinations of PASI and DLQI as independent variables. ResultsThe adjusted regression models showed that patients with high PASI score and low DLQI score had a higher chance to receive biological treatment compared to patients with low PASI score and high DLQI score. ConclusionThe decision to initiate biological treatment is more strongly associated with PASI than with DLQI. However, since the DLQI reflects both socio-economic costs and patient suffering better than PASI, the relevance of the DLQI may be underestimated in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据